Cold Agglutinin Disease Real World Evidence Registry
Cold Agglutinin Disease Real World Evidence Registry
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 [NCT02502903,CAD patients], BIVV009-03/EFC16215 [NCT03347396], and BIVV009-04/EFC16216 [NCT03347422]) and who either completed or discontinued the corresponding clinical trial are eligible to participate in the registry.
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20007, United States
Sioux City, Iowa 51101, United States
Lake Success, New York 11042, United States
Greenville, North Carolina 27834, United States
Pittsburgh, Pennsylvania 15232, United States
Seattle, Washington 98109, United States
Epagny-Metz-Tessy, 74370, France
Himeji-shi, Hyōgo 670-0063, Japan